Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis

被引:31
作者
Paulke-Korinek, Maria [1 ,2 ]
Kollaritsch, Herwig [1 ]
Kundi, Michael [3 ]
Zwazl, Ines [1 ]
Seidl-Friedrich, Claudia [1 ]
Jelinek, Tomas [4 ]
机构
[1] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria
[2] Fed Minist Hlth, Vienna, Austria
[3] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria
[4] Berlin Ctr Travel & Trop Med, Berlin, Germany
关键词
Japanese encephalitis vaccine; Long-term protection; Low responder; IMMUNITY; CELLS; TBE;
D O I
10.1016/j.vaccine.2015.05.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Japanese Encephalitis (JE) virus occurs in wide regions of Asia with over 3 billion people living in areas at risk for JE. An estimated 68,000 clinical cases of JE occur every year, and vaccination is the most effective prophylactic measure. One internationally licensed vaccine containing the inactivated JE virus strain SA(14)-14-2 is lxiaro (R) (Valneva, Austria). According to recommendations, basic immunization consists of vaccinations on day 0, day 28, and a booster dose 12-24 months later. Protection in terms of neutralizing antibody titers has been assessed up to 12 months after the third dose of the vaccine. The current investigation was designed to evaluate antibody decline over time and to predict long-term duration of seroprotection after a booster dose. Method: In a preceding trial, volunteers received basic immunization (day 0, day 28) and one booster dose against JE 15 months later. A follow up blood draw 6 years following their booster dose was carried out in 67 subjects. For antibody testing, a 50% plaque reduction neutralization test (PRNT50-test) was used. PRNT50 values of 10 and above are surrogate levels of protection according to WHO standards. Result: Seventy-six months following the booster dose, 96% of the tested subjects had PRNT50 titers of 10 or higher. Geometric mean titer (GMT) was 148 (95% CI confidence interval: 107-207). Antibody titers were lower in volunteers 50 years of age and older. Vaccination history against other flaviviruses (yellow fever or tick borne encephalitis) did not significantly influence PRNT50 titers. A two-step log-linear decline model predicted protection against JE of approximately 14 years after the booster dose. Conclusion: Six years after a booster dose against JE, long-term protection could be demonstrated. According to our results, further booster doses should be scheduled 10 years following the first booster dose. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3600 / 3604
页数:5
相关论文
共 50 条
  • [41] Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: Immunogenicity 5 years post-vaccination
    McIntyre, Peter B.
    Burgess, Margaret A.
    Egan, Annemarie
    Schuerman, Lode
    Hoet, Bernard
    VACCINE, 2009, 27 (07) : 1062 - 1066
  • [42] Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization
    Feroldi, Emmanuel
    Boaz, Mark
    Yoksan, Sutee
    Chokephaibulkit, Kulkanya
    Thisyakorn, Usa
    Pancharoen, Chitsanu
    Monfredo, Celine
    Bouckenooghe, Alain
    JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (02) : 221 - 227
  • [43] Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults
    Van Damme, P
    Leroux-Roels, G
    Law, B
    Diaz-Mitoma, F
    Desombere, I
    Collard, F
    Tornieporth, N
    Van Herck, K
    JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (01) : 6 - 13
  • [44] Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial
    Yun, Ki Wook
    Lee, Hoan Jong
    Kang, Jin Han
    Eun, Byung Wook
    Kim, Yae-Jean
    Kim, Kyung-Hyo
    Kim, Nam Hee
    Hong, Young Jin
    Kim, Dong Ho
    Kim, Hwang Min
    Cha, Sung-Ho
    BMC INFECTIOUS DISEASES, 2015, 15
  • [45] Antibody Responses Induced by Experimental West Nile Virus Infection with or without Previous Immunization with Inactivated Japanese Encephalitis Vaccine in Horses
    Shirafuji, Hiroaki
    Kanehira, Katslshi
    Kamio, Tsugihiko
    Kubo, Masanori
    Shibahara, Tomoyuki
    Konishi, Misako
    Murakami, Kenji
    Nakamura, Yoshio
    Yamanaka, Takashi
    Kondo, Takashi
    Matsumura, Tomio
    Muranaka, Masanori
    Katayama, Yoshinari
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2009, 71 (07) : 969 - 974
  • [46] SARS-CoV-2 antibodies after booster vaccination. Identification of subgroups with poor response
    Garcia, B. Ayuso
    Lema, E. M. Romay
    Lopez, A. Perez
    Pinera, A. Suarez
    Belay, M. C. Pereiro
    Gonzalez, M. J. Gude
    Rey, R. Rabunal
    REVISTA CLINICA ESPANOLA, 2023, 223 (06): : 379 - 382
  • [47] Five year follow-up after primary vaccination against tick-borne encephalitis in children
    Wittermann, Christoph
    Izu, Allen
    Petri, Eckhardt
    Gniel, Dieter
    Fragapane, Elena
    VACCINE, 2015, 33 (15) : 1824 - 1829
  • [48] Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine
    Vodopija, R
    Lafont, M
    Baklaic, Z
    Ljubicic, M
    Svjetlicic, M
    Vodopija, I
    VACCINE, 1997, 15 (05) : 571 - 574
  • [49] Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety
    Kling, Kerstin
    Harder, Thomas
    Younger, Zane
    Burchard, Gerd
    Schmidt-Chanasit, Jonas
    Wichmann, Ole
    JOURNAL OF TRAVEL MEDICINE, 2020, 27 (02)
  • [50] Persistence of Rubella Antibodies after 2 Doses of Measles-Mumps-Rubella Vaccine
    LeBaron, Charles W.
    Forghani, Bagher
    Matter, Lukas
    Reef, Susan E.
    Beck, Carol
    Bi, Daoling
    Cossen, Cynthia
    Sullivan, Bradley J.
    JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (06) : 888 - 899